Cross-clade T cell recognition of HIV.1.
Despite considerable advances in antiviral therapy for HIV infection, successful global intervention will require an effective vaccine. Current evidence suggests that cytotoxic T lymphocyte responses will be an important component of such vaccination. Recent evidence suggests that cytotoxic T lymphocytes raised against viral antigens from different clades (subtypes) of HIV.1 can cross-react extensively and such data have major implications for HIV vaccine design.